Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Tafamidis

Generic Name: Tafamidis

Brand Names: Vyndamax, Vyndaqel

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₇Cl_₂NO_₃

CAS Number: 594839-88-0

Unique Ingredient Identifier: 8FG9H9D31J

Overview

Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.

Background

Indication

Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.

Associated Conditions

Cardiomyopathy

Clinical Trials

A Study to Determine the Bioequivalence of Two Doses of Tafamidis

Phase 1

Completed

Posted: 2020/10/05

Sponsor:Pfizer

ID:NCT04575116

A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics

Phase 1

Completed

Posted: 2020/02/05

Sponsor:Pfizer

ID:NCT04253353

Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)

Phase 1

Completed

Posted: 2018/09/07

Sponsor:Pfizer

ID:NCT03662191

A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood

Phase 1

Completed

Posted: 2017/09/12

Sponsor:Pfizer

ID:NCT03280173

A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood

Phase 1

Completed

Posted: 2017/08/30

Sponsor:Pfizer

ID:NCT03266705

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

FDA Advisory Panel Backs Alnylam's Onpattro for ATTR Cardiomyopathy Despite Efficacy Concerns

2 months ago

An FDA advisory committee voted 9-3 in favor of approving Alnylam's Onpattro (patisiran) for transthyretin amyloidosis cardiomyopathy (ATTR-CM), with a final decision expected by October 8th.

Alnylam's Vutrisiran Shows Strong Efficacy in ATTR Cardiomyopathy, Setting Stage for New Treatment Standard

3 months ago

Alnylam's RNAi drug vutrisiran demonstrated a 28% reduction in all-cause mortality and recurrent cardiovascular events in ATTR cardiomyopathy patients, with efficacy increasing to 33% in patients not taking Pfizer's tafamidis.

FDA Approves Genentech's TNKase for Acute Ischemic Stroke with Simplified Administration

3 months ago

The FDA has approved Genentech's TNKase, a clot-dissolving agent, for treating acute ischemic stroke in adults, marking the company's second stroke treatment approval.

Kailera's HRS9531 Shows Strong Phase II Weight Loss, Pfizer Cautious on Danuglipron

4 months ago

Kailera Therapeutics' HRS9531, a dual GLP-1/GIP receptor agonist, demonstrated a 21.1% placebo-adjusted weight reduction in Phase II trials over 36 weeks.

FDA Approves BridgeBio's Attruby, Setting Up Competition with Pfizer's Vyndamax in ATTR-CM Market

6 months ago

The FDA has approved BridgeBio Pharma's Attruby (acoramidis) for transthyretin amyloidosis cardiomyopathy (ATTR-CM), a heart condition leading to heart failure and death.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy